2016 Fiscal Year Final Research Report
Overcome of intractable radiation necrosis. Bevacizumab therapy and beyond bevacizumab
| Project/Area Number |
26462222
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
NONOGUCHI Naosuke
TOHO Taichiro
TSUJI Yuichiro
FUKUMURA Masao
YOSHIKAWA Masashi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 放射線壊死 / ベバシズマブ / 神経膠腫 / 髄膜腫 / VEGF |
|---|
| Outline of Final Research Achievements |
The aim of this study was to concur radiation necrosis of the brain. In a laboratory study, an optical radiation dose for formation of radiation necrosis was clarified in rats. Radiation necrosis stably appeared 6 months after 65 Gy of a single fraction. In the next study, key molecules for radiation necrosis will be elucidated using this model. In a clinical study, bevacizumab suppressed radiation necrosis, but not tumor tissue in previously irradiated meningioma. Recurrent meningioma could be distinguished from radiation necrosis by administration of bevacizumab. In radiation necrosis, efficacy of bevacizumab lasted 6 months after completion of bevacizumab therapy. And we reported pathological review of brain radiation necrosis.
|
| Free Research Field |
脳腫瘍
|
